Kenvue Q2 net sales +3.0%, adj. EPS $0.31 (+7% YoY); reaffirms Q4 Kimberly-Clark deal close

Kenvue Inc.

Net sales $3.0B, +3.0% YoY; organic sales +1.6% driven by value realization +0.9% and volume +0.7%.
Diluted EPS $0.24 (+9% YoY); adjusted diluted EPS $0.31 (+7% YoY); adjusted gross margin 60.2%.
Skin Health & Beauty led with +5.1% net sales; Self Care +2.2%, Essential Health +2.3%.
FDA approved Tylenol with Naproxen (first OTC fixed-dose combo); 3-year exclusivity, launching soon.
Pending Kimberly-Clark acquisition on track for Q4 2026; no forward guidance provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.